with the latter expected to enter clinical trials in 2025 for hepatocellular carcinoma. The technology offers several advantages, including moderate potency to enable higher ADC dosing and ...

with the latter expected to enter clinical trials in 2025 for hepatocellular carcinoma. The technology offers several advantages, including moderate potency to enable higher ADC dosing and bystander ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment of unresectable hepatocellular carcinoma ... Biopsy was obtained and ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

Aim: To compare the new, 6th edition, UICC TNM staging system with the former edition, we updated TNM staging in patients with differentiated thyroid carcinoma. Methods: The new and old TNM ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Shown are the genetic variants identified in EPO, the gene encoding erythropoietin (EPO), in patients with erythrocytosis. The term cDNA denotes complementary DNA, F female, M male, and NA not ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside potential for investors. Learn more on ZYME stock here.